Boston Scientific Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael F. Mahoney
- Full Time Employees
- 59,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 300 Boston Scientific Way Marlborough MA United States of America 01752-1234
- IPO Date
- May 19, 1992
- CIK
- 0000885725
- Website
- bostonscientific.com
- Similar Companies
- Business
- Boston Scientific Corporation (NYSE: BSX) develops, manufactures and markets innovative medical devices for a wide range of interventional medical specialties worldwide. The company operates through two primary reportable segments, MedSurg and Cardiovascular, encompassing eight core businesses: Cardiac Rhythm Management, Electrophysiology, Endoscopy, Interventional Cardiology Therapies, Neuromodulation, Peripheral Interventions, Urology and WATCHMAN; its product portfolio includes pacemakers, defibrillators (S-ICD, ICD), CRT-P devices, deep brain stimulation systems, radiofrequency ablation systems for pain management, renal denervation technologies, direct visualization systems, embolic protection and embolization devices, FFR and IVUS systems, guidewires, imaging systems, intragastric balloons, lasers for BPH and lithotripsy, plaque modification tools, retrieval devices, RF ablation systems, hemostasis needles, hepatopancreatobiliary stents, hydrogel spacers, infection prevention products, pelvic floor reconstruction devices, penile prostheses and single-use imaging systems. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company maintains commercial operations in over 127 countries, including the U.S., Europe, Middle East and Africa, Asia-Pacific, Latin America and Canada, serving approximately 44 million patients annually through healthcare professionals in fields such as interventional cardiology, endoscopy, neuromodulation, peripheral interventions and urology. In recent developments, Boston Scientific has pursued an aggressive acquisition strategy, including agreements to acquire Bolt Medical for up to $664 million to enhance its intravascular lithotripsy offerings for coronary and peripheral artery disease (expected close in first half of 2025), SoniVie Ltd. for up to $600 million to advance therapeutic intravascular ultrasound for renal denervation in hypertension treatment (expected close in first half of 2025), Elutia's BioEnvelope division to reduce complications in cardiac rhythm management devices, Anrei Medical for $182 million to bolster endoscopy solutions, Intera Oncology for interventional oncology in liver metastases, and Cortex; the company also completed its $3.7 billion acquisition of Axonics in November 2024 and received $2.6 million in state funding for a 52,000-square-foot manufacturing expansion at its Maple Grove, Minnesota campus to support WATCHMAN product growth, alongside launching approximately 100 new products in 2024.
Company News
Perpetual Ltd Purchases 24,355 Shares of Boston Scientific Corporation $BSX
Boston Scientific (NYSE:BSX) and Sysmex (OTCMKTS:SSMXY) Critical Survey
Why Boston Scientific (BSX) Outpaced the Stock Market Today
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know
Boston Scientific (NYSE:BSX) Reaches New 1-Year Low – Time to Sell?
Boston Scientific (NYSE: BSX) names Fitzgerald COO, splits into 3 segments
Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Boston Scientific's MedSurg Diversification Bolsters Growth Prospects
Boston Scientific Corporation (NYSE:BSX) Stock Has Average Price Target of $70.19
Rep. Kevin Hern Sells Shares of Boston Scientific Corporation (NYSE:BSX)
Boston Scientific: Market Pessimism Has Pushed The Stock Into Undervalued Territory
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?
New Strong Sell Stocks for September 21st
BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?
Boston Scientific Corporation $BSX Shares Acquired by Corient Private Wealth LP
New Strong Sell Stocks for September 16th